What is known about the safety of dalteparin sodium during breastfeeding?

For Fragmin (dalteparin sodium), milk-excretion data are limited and an anticoagulant effect on the infant appears unlikely, but risk cannot be excluded, so continuing or stopping breastfeeding or treatment requires weighing breastfeeding benefits for the child against treatment benefits for the woman.